S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
NASDAQ:BFRI

Biofrontera (BFRI) Stock Forecast, Price & News

$0.46
0.00 (0.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$0.46
$0.49
50-Day Range
$0.40
$0.65
52-Week Range
$0.37
$2.86
Volume
11,896 shs
Average Volume
122,623 shs
Market Capitalization
$12.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Biofrontera MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,405.4% Upside
$7.00 Price Target
Short Interest
Healthy
1.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.25mentions of Biofrontera in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.79) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

1003rd out of 1,980 stocks

Pharmaceutical Preparations Industry

485th out of 978 stocks


BFRI stock logo

About Biofrontera (NASDAQ:BFRI) Stock

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.

Receive BFRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

BFRI Stock News Headlines

How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
Biofrontera Inc. Announces Resignation of CEO
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
Biofrontera (BFRI) to Release Earnings on Friday
Biofrontera Inc. Common Stock (BFRI)
See More Headlines

BFRI Price History

BFRI Company Calendar

Last Earnings
3/13/2023
Today
6/01/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BFRI
Fax
N/A
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+1,405.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-640,000.00
Pretax Margin
-49.44%

Debt

Sales & Book Value

Annual Sales
$28.67 million
Book Value
$0.63 per share

Miscellaneous

Free Float
26,528,000
Market Cap
$12.42 million
Optionable
Not Optionable
Beta
0.95

Key Executives

  • Dr. Hermann Lubbert Ph.D. (Age 67)
    Exec. Chairman & Pres
    Comp: $18.02k
  • Ms. Erica L. Monaco CPA (Age 38)
    CEO, COO, Treasurer & Sec.
    Comp: $402.12k
  • Mr. Eugene Fredrick Leffler III (Age 39)
    Chief Financial Officer
  • Ms. Erica F. Gates CPA
    M.B.A., Sr. Director of Fin. & Principal Accounting Officer
  • Ms. Alycia Torres
    VP of Admin.
  • Mr. Daniel Hakansson J.D.
    Gen. Counsel & Head of Compliance
  • Mr. Mark Baldyga
    Head of Sales & Marketing
  • Mr. Jeff Holm
    Head of Professional Relations & Commercial Devel.













BFRI Stock - Frequently Asked Questions

Should I buy or sell Biofrontera stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BFRI shares.
View BFRI analyst ratings
or view top-rated stocks.

What is Biofrontera's stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month target prices for Biofrontera's stock. Their BFRI share price forecasts range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,405.4% from the stock's current price.
View analysts price targets for BFRI
or view top-rated stocks among Wall Street analysts.

How have BFRI shares performed in 2023?

Biofrontera's stock was trading at $0.9166 at the beginning of the year. Since then, BFRI stock has decreased by 49.3% and is now trading at $0.4650.
View the best growth stocks for 2023 here
.

Are investors shorting Biofrontera?

Biofrontera saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 270,800 shares, an increase of 12.3% from the April 30th total of 241,200 shares. Based on an average trading volume of 95,100 shares, the days-to-cover ratio is presently 2.8 days. Approximately 1.8% of the shares of the company are short sold.
View Biofrontera's Short Interest
.

When is Biofrontera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our BFRI earnings forecast
.

How were Biofrontera's earnings last quarter?

Biofrontera Inc. (NASDAQ:BFRI) released its earnings results on Monday, March, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The company earned $10.14 million during the quarter, compared to analysts' expectations of $10.32 million. Biofrontera had a negative trailing twelve-month return on equity of 109.94% and a negative net margin of 49.46%.

What guidance has Biofrontera issued on next quarter's earnings?

Biofrontera issued an update on its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $35.84M-, compared to the consensus revenue estimate of $36.50 million.

When did Biofrontera IPO?

(BFRI) raised $19 million in an IPO on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO.

What is Biofrontera's stock symbol?

Biofrontera trades on the NASDAQ under the ticker symbol "BFRI."

How do I buy shares of Biofrontera?

Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biofrontera's stock price today?

One share of BFRI stock can currently be purchased for approximately $0.47.

How much money does Biofrontera make?

Biofrontera (NASDAQ:BFRI) has a market capitalization of $12.42 million and generates $28.67 million in revenue each year. The company earns $-640,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

How can I contact Biofrontera?

The official website for the company is www.biofrontera-us.com. The company can be reached via phone at 781-245-1325 or via email at us-ir@biofrontera.com.

This page (NASDAQ:BFRI) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -